anayamalik, Author at European Medical Journal - Page 79 of 128

Genetic Clues Behind P. aeruginosa Drug Resistance

Pseudomonas aeruginosa, a leading cause of microbial keratitis, continues to challenge clinicians with rising antimicrobial resistance.

New Treatment Cuts Exacerbations in Bronchiectasis

Targeting inflammation at its root, a new therapy reduces bronchiectasis exacerbations and slows lung function decline, according to results from a Phase III clinical trial.

Targeted RA Therapies: Lessons from Aging Japan

In Japan, home to the world’s most rapidly aging society, managing rheumatoid arthritis (RA) in elderly patients has posed unique challenges for healthcare providers.

Dermatology Trials Face a Reckoning on Race and Ethnicity

In dermatology research, the use of race and ethnicity as population descriptors has come under increasing scrutiny, with experts questioning whether these broad categories obscure more than they reveal about human health.

What Drives Survival in HER2+ Breast Cancer?

In a real-world study examining neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive (HER2+) breast cancer, researchers have identified key predictors of treatment response and long-term survival, providing critical insights for oncologists managing this aggressive disease.

New MRI Measures Offer Clues to Preclinical Alzheimer’s

MRI continues to play a pivotal role in the early detection of Alzheimer’s disease, and new research suggests that using distance measures from MRI data may outperform traditional volumetric assessments in predicting cognitive decline.

Managing Elevated CRP in Sleep Apnea: New Insights

Severe obstructive sleep apnea (OSA) is independently associated with elevated C-reactive protein (CRP) levels, a key marker of systemic inflammation and cardiovascular risk, according to new research analyzing over 2,400 patients.

FMT at Home Cuts CDI Hospitalization Time

Clostridioides difficile infection (CDI) remains a pressing challenge in older adults, particularly those with comorbidities, leading to significant mortality and healthcare costs.

Multimorbidity in Systemic Sclerosis: Hidden Driver of Poor Outcomes

Multimorbidity, the presence of multiple co-existing health conditions, has emerged as a critical factor influencing survival and physical function in patients with systemic sclerosis (SSc), according to a large cohort study of 2,000 participants.

Emerging Guidelines: Photobiomodulation in Focus

Healthcare professionals treating conditions such as peripheral neuropathy, wound ulcers, or radiation dermatitis now have fresh, evidence-based guidance on the use of photobiomodulation (PBM) therapy.